Quantcast

Mid-Afternoon Market Update: Dow Up Over 100 Points; Achieve Life Sciences Shares Spike Higher


Shutterstock photo

Toward the end of trading Tuesday, the Dow traded up 0.49 percent to 24,370.33 while the NASDAQ climbed 0.85 percent to 7,596.27 . The S&P also rose, gaining 0.54 percent to 2,731.75 .

Leading and Lagging Sectors

Tuesday afternoon, the energy shares surged 1.1 percent. Meanwhile, top gainers in the sector included NextDecade Corporation (NASDAQ: NEXT ) up 10 percent, and Clean Energy Fuels Corp. (NASDAQ: CLNE ) up 9 percent.

In trading on Tuesday, telecommunication services shares fell 0.76 percent.

Top Headline

Lennar Corporation (NYSE: LEN ) reported better-than-expected results for its fiscal second quarter.

Lennar said it earned $1.58 per share in the quarter on revenue of $5.459 billion versus expectations of 45 cents and $5.1 billion.

Equities Trading UP

TSR, Inc. (NASDAQ: TSRI ) shares shot up 37 percent to $8.30 after James Hughes requested TSR pursue a sale of the company.

Shares of Lee Enterprises, Incorporated (NYSE: LEE ) got a boost, shooting up 27 percent to $3.05. The provider of local news and information, and a major platform for advertising said it reached an agreement to manage Berkshire Hathaway's newspaper and digital operations in 30 markets.

Achieve Life Sciences, Inc. (NASDAQ: ACHV ) shares were also up, gaining 29 percent to $4.90. The clinical-stage pharmaceutical company said its product candidate cytosine, an aid to smoking cessation, realized positive results from a series of drug metabolism. This suggests cytisine may be administered with other medications without the need to modify the dose of the co-administered drug.

Equities Trading DOWN

Gevo, Inc. (NASDAQ: GEVO ) shares dropped 18 percent to $8.16 following announcement of $8 million at-the-market common stock offering.

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) were down 15 percent to $3.9177. SELLAS Life Sciences reported a proposed 6.017 million share public offering of common stock.

Achaogen, Inc. (NASDAQ: AKAO ) was down, falling around 24 percent to $9.11. Achaogen's tryst with the FDA regarding its anti-bacterial agent plazomicin, as expected, ended with a mixed outcome, just as the FDA panel issued a split verdict on it when it met in May. Achaogen announced Tuesday its Zemdri, the trade name for plazomicin, was greenlighted by the FDA for treating adults with complicated urinary tract infections including pyelonephritis, due to certain Enterobacteriaceae for which there's limited or no alternative treatment option.

Commodities

In commodity news, oil traded up 3.53 percent to $70.48 while gold traded down 0.46 percent to $1,263.00.

Silver traded down 0.20 percent Tuesday to $16.295, while copper rose 0.10 to $3.0125.

Eurozone

European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.02 percent, the Spanish Ibex Index rose 0.20 percent, while Italy's FTSE MIB Index climbed 0.30 percent. Meanwhile the German DAX dropped 0.29 percent, and the French CAC 40 slipped 0.05 percent while U.K. shares rose 0.37 percent.

Economics

The S&P Corelogic Case-Shiller home price index increased a seasonally adjusted 0.2 percent in April.

The Conference Board's consumer confidence index declined to 126.4 in June, versus a revised reading of 128.8 in May. However, economists projected a reading of 128.0.

The Richmond Fed's manufacturing index climbed to 20.00 for June, versus prior reading of 16.00. However, economists were expecting a reading of 15.00.

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Commodities
Referenced Symbols: CLNE , TSRI , LEE , LEN , SLS



More from Benzinga

Subscribe






Contributor:

Benzinga

Market Analysis, FinTech










Research Brokers before you trade

Want to trade FX?